Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

FATE Relative to the S&P 500

FATE Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Fate Therapeutics, Inc. (NASD:FATE) seasonal charts above shows that a Buy Date of November 10 and a Sell Date of March 19 has resulted in a geometric average return of 26.9% above the benchmark rate of the S&P 500 Total Return Index over the past 11 years. This seasonal timeframe has shown positive results compared to the benchmark in 8 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 11 years by an average of 49.21% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company’s cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

To download FATE seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: FATE